We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
American Vanguard Corp
AVD
$74.1M
| $1.43M | 0.01% |
249,136
-98,264
| -28% | -$468K |
|
652
Vertiv
VRT
$104B
| $1.43M | 0.01% |
9,475
+1,428
| +18% | +$190K |
|
|
BKV
653
BKV Corp
BKV
$2.57B
| $1.42M | 0.01% |
61,339
+14,992
| +32% | +$327K |
|
654
Biogen
BIIB
$30.4B
| $1.42M | 0.01% |
10,124
-2,501
| -20% | -$338K |
|
655
Inseego
INSG
$111M
| $1.42M | 0.01% |
94,572
-66,663
| -41% | -$671K |
|
656
StoneX
SNEX
$8.99B
| $1.41M | 0.01% |
31,327
-5,420
| -15% | -$230K |
|
657
Chegg
CHGG
$121M
| $1.4M | 0.01% |
930,177
+645,874
| +227% | +$908K |
|
658
Preformed Line Products
PLPC
$1.45B
| $1.39M | 0.01% |
7,085
| – | – |
|
659
Herc Holdings
HRI
$4.95B
| $1.38M | 0.01% |
11,789
-14,917
| -56% | -$1.92M |
|
660
National Fuel Gas
NFG
$7.73B
| $1.37M | 0.01% |
14,876
-3,229
| -18% | -$281K |
|
661
MacroGenics
MGNX
$245M
| $1.37M | 0.01% |
815,865
-188,933
| -19% | -$306K |
|
662
Amer Sports
AS
$20.9B
| $1.34M | 0.01% |
+38,456
| New | +$1.45M |
|
663
Stoneridge
SRI
$208M
| $1.33M | 0.01% |
174,499
-31,155
| -15% | -$247K |
|
664
TriCo Bancshares
TCBK
$1.85B
| $1.33M | 0.01% |
29,925
-3,258
| -10% | -$142K |
|
665
CS Disco
LAW
$270M
| $1.33M | 0.01% |
205,372
+2,045
| +1% | +$10.2K |
|
666
NovoCure
NVCR
$1.89B
| $1.33M | 0.01% |
102,563
-45,638
| -31% | -$610K |
|
667
A10 Networks
ATEN
$2.25B
| $1.28M | 0.01% |
70,739
-407,774
| -85% | -$7.38M |
|
668
Liberty Latin America Class C
LILAK
$1.65B
| $1.28M | 0.01% |
167,097
-176,986
| -51% | -$1.21M |
|
669
AMN Healthcare
AMN
$1.35B
| $1.27M | 0.01% |
65,593
+31,453
| +92% | +$614K |
|
670
Rimini Street
RMNI
$453M
| $1.26M | 0.01% |
269,706
+22,454
| +9% | +$99.7K |
|
|
BBT
671
Beacon Financial Corp
BBT
$2.51B
| $1.26M | 0.01% |
53,232
-133,894
| -72% | -$3.43M |
|
|
BIOA
672
BioAge Labs
BIOA
$974M
| $1.25M | 0.01% |
213,088
-60,364
| -22% | -$283K |
|
673
Amdocs
DOX
$5.83B
| $1.25M | 0.01% |
15,231
-3,401
| -18% | -$295K |
|
674
Urban Outfitters
URBN
$6.44B
| $1.25M | 0.01% |
17,476
-12,726
| -42% | -$936K |
|
|
CFLT
675
DELISTED
Confluent
CFLT
| $1.24M | ﹤0.01% |
+62,404
| New | +$1.31M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.